Finrozole
| Names | |
|---|---|
| Preferred IUPAC name
4-[(1R,2S)-3-(4-Fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)propyl]benzonitrile | |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.219.051 |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Pharmacology | |
| QG03XX90 (WHO) | |
| Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Finrozole is an aromatase (CYP19A1) inhibitor.[2]
Finrozole was authorized for veterinary use in the European Union in April 2025.[1]
Medical uses
Finrozole is indicated to shorten the pro-oestrus and oestrus period, reduce clinical signs of heat and reduce the risk of pregnancy.[1]
References
- ^ a b c "Prevestrus vet PI". Union Register of medicinal products. 25 April 2025. Retrieved 3 May 2025.
- ^ Huuskonen, P; Myllynen, P; Storvik, M; Pasanen, M (2013). "The effects of aflatoxin B1 on transporters and steroid metabolizing enzymes in JEG-3 cells". Toxicology Letters. 218 (3): 200–6. doi:10.1016/j.toxlet.2013.01.015. PMID 23402939.